House Appropriators Will Tell US FDA 'Don't Finalize' LDT Guidance In 2018 Funding Bill

When the House Appropriations Committee takes up the US FDA funding bill for 2018, report language would "prevent the agency from finalizing a guidance on regulating laboratory developed tests," Rep. Rosa DeLauro said at a June 28 Ag/FDA subcommittee markup. The House bill, while maintaining FDA discretionary funding at its prior-year $2.8bn level, also fully appropriates user fee authorizations agreed to by Senate and House Committees in FDA Reauthorization bills in May and June, respectively.

A rider "that prevents FDA from finalizing guidance on laboratory-developed tests" will appear in report language for the House's FY 2018 FDA appropriations bill, Rep. Rosa DeLauro, D-Conn., said at a June 28 House Appropriations Committee, Agriculture and FDA subpanel markup. The rider follows FDA's decision in January to put off long-held plans to finalize a regulatory framework guidance for LDTs, leaving it up to Congress to figure out the best regulatory pathway for the diagnostic services.

DeLauro said she has "concerns" about the report language, which from her perspective, leaves LDTs "unregulated."

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Legislation

More from Policy & Regulation